

THIS IS A PUBLIC ANNOUNCEMENT FOR INFORMATION PURPOSES ONLY AND IS NOT A PROSPECTUS ANNOUNCEMENT AND DOES NOT CONSTITUTE AN INVITATION OR OFFER TO ACQUIRE, PURCHASE OR SUBSCRIBE TO SECURITIES. NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION DIRECTLY OR INDIRECTLY OUTSIDE INDIA.



Krsnaa
DIAGNOSTICS®
LET'S DO GOOD...®

KRSNAA DIAGNOSTICS LIMITED

Krsnaa Diagnostics Limited (our “Company” or the “Issuer”) was originally incorporated as ‘Krsna Diagnostics Private Limited’ at Pune, Maharashtra as a private limited company under the Companies Act, 1956, pursuant to a certificate of incorporation dated December 22, 2010, issued by the Registrar of Companies, Maharashtra at Pune (“RoC”). The name of our Company was subsequently changed to ‘Krsnaa Diagnostics Private Limited’, pursuant to a fresh certificate of incorporation issued by the RoC on January 29, 2015. Thereafter, our Company was converted into a public limited company pursuant to a special resolution passed in the extraordinary general meeting of the Shareholders of our Company held on April 25, 2021 and consequently the name of our Company was changed to its present name pursuant to a fresh certificate of incorporation issued by the RoC on May 6, 2021. For further details relating to the changes in the name of our Company and the registered office of our Company, see “History and Certain Corporate Matters” on page 168 of the Red Herring Prospectus dated July 29, 2021 (“RHP”).

Registered and Corporate Office: S.No. 243/A, Hissa No. 6, CTS No. 4519, 4519/1, Near Chinchwad Station, Chinchwad, Taluka – Haveli, Pune - 411 019, Maharashtra;
Telephone: +91 20 4695 4695; **Contact Person:** Manisha Chitgopekar, Company Secretary and Compliance Officer; **E-mail:** cs@krsnadiagnostics.com;
Website: www.krsnaadiagnostics.com, **Corporate Identity Number:** U74900PN2010PLC138068;

OUR PROMOTER: RAJENDRA MUTHA

INITIAL PUBLIC OFFERING OF UP TO [●] EQUITY SHARES OF FACE VALUE OF ₹5 EACH (“EQUITY SHARES”) OF OUR COMPANY FOR CASH AT A PRICE OF ₹[●] PER EQUITY SHARE (INCLUDING A PREMIUM OF ₹[●] PER EQUITY SHARE) (“OFFER PRICE”) AGGREGATING UP TO ₹[●] MILLION (“OFFER”). THE OFFER COMPRISES OF A FRESH ISSUE OF UP TO [●] EQUITY SHARES AGGREGATING UP TO ₹4,000.00 MILLION (“FRESH ISSUE”) AND AN OFFER FOR SALE OF UP TO 8,525,520 EQUITY SHARES (“OFFERED SHARES”) AGGREGATING UP TO ₹[●] MILLION, COMPRISING UP TO 1,600,000 EQUITY SHARES AGGREGATING TO ₹[●] MILLION BY PHI CAPITAL TRUST-PHI CAPITAL GROWTH FUND-I, (“SELLING SHAREHOLDER 1”), UP TO 3,340,713 EQUITY SHARES AGGREGATING UP TO ₹[●] MILLION BY KITARA PIIN 1104 (“SELLING SHAREHOLDER 2”), UP TO 3,563,427 EQUITY SHARES AGGREGATING UP TO ₹[●] MILLION BY SOMERSET INDUS HEALTHCARE FUND I LIMITED (“SELLING SHAREHOLDER 3”) AND UP TO 21,380 EQUITY SHARES AGGREGATING UP TO ₹[●] MILLION BY LOTUS MANAGEMENT SOLUTIONS (ACTING THROUGH MAYUR SIRDESAI) (“SELLING SHAREHOLDER 4”) AND TOGETHER WITH SELLING SHAREHOLDER 1, SELLING SHAREHOLDER 2 AND SELLING SHAREHOLDER 3, THE “SELLING SHAREHOLDERS” AND SUCH OFFER, THE “OFFER FOR SALE”. THE OFFER INCLUDES A RESERVATION OF UP TO [●] EQUITY SHARES AGGREGATING UP TO ₹200.00 MILLION, FOR SUBSCRIPTION BY ELIGIBLE EMPLOYEES (THE “EMPLOYEE RESERVATION PORTION”). THE OFFER LESS THE EMPLOYEE RESERVATION PORTION IS HEREINAFTER REFERRED TO AS THE “NET OFFER”. THE OFFER AND THE NET OFFER WILL CONSTITUTE [●]% AND [●]% OF THE POST-OFFER PAID-UP EQUITY SHARE CAPITAL OF OUR COMPANY, RESPECTIVELY.

Retail Individual Bidders Portion: Not More than 10% of the Net Offer
Non-Institutional Bidders Portion: Not More than 15% of the Net Offer

QIB Portion: Not Less than 75% of the Net Offer
Employee Reservation Portion: Upto ₹ 200 million

Price Band: ₹ 933 to ₹ 954 per Equity Share of face value of ₹5 each.

The Floor Price is 186.60 times the face value of the Equity Shares and the Cap Price is 190.80 times the face value of the Equity Shares.

Bids can be made for a minimum of 15 Equity Shares and in multiples of 15 Equity Shares thereafter.

A Discount of ₹ 93 per Equity Share is being Offered to Eligible Employees

Bidding in the Employee Reservation Portion.

ASBA[#]

**Simple, Safe,
Smart way of
Application!!!**

Applications supported by blocked amount (ASBA) is a better way of applying to issues by simply blocking the fund in the bank account. For further details, check section on ASBA below.
Mandatory in public issues. No cheque will be accepted.



UPI-Now available in ASBA for Retail Individual Bidders (“RIBs”) applying through Registered Brokers, Syndicate, DPs and RTAs. RIBs also have the option to submit the application directly to the ASBA Bank (SCSBs) or to use the facility of linked online trading, demat and bank account.

Bidders are required to ensure that the bank account used for bidding is linked to their PAN.

ASBA has to be availed by all the investors except anchor investors. UPI may be availed by Retail Individual Bidders. For details on the ASBA and UPI process, please refer to the details given in ASBA form and abridged prospectus and also please refer to the section “Offer Procedure” on page 355 of the RHP. The process is also available on the website of Association of Investment Bankers of India (“AIBI”) and Stock Exchanges in the General Information Document. ASBA bid-cum-application forms can be downloaded from the websites of BSE Limited (“BSE”) and National Stock Exchange of India Limited (“NSE”), and together with BSE, the “Stock Exchanges” and can be obtained from the list of banks that is displayed on the website of SEBI at www.sebi.gov.in. List of banks supporting UPI is also available on the website of www.sebi.gov.in. ICICI Bank Limited has been appointed as Sponsor Bank for the Offer, in accordance with the requirements of the SEBI UPI Circular dated November 1, 2018 as amended. For Offer related queries or UPI related queries, investors may contact: JM Financial Limited - Prachee Dhuri (+ 91 22 6630 3030) (krsnaadiagnostics ipo@jmf.com, grievance.ibd@jmf.com); DAM Capital Advisors Limited (Formerly IDFC Securities Limited) - Chandresh Sharma (+91 22 4202 2500) (krsnaa.ipo@damcapital.in, complaint@damcapital.in); Equirus Capital Private Limited - Ansh Jain (+91 22 4332 0700) (krsnaa.ipo@equirus.com, investorsgrievance@equirus.com); IIFL Securities Limited - Aditya Agarwal / Harshvardhan Jain (+91 22 4646 4600) (krsnaa.ipo@iiflcap.com, ig_ib@iiflcap.com). For UPI related queries, investors can contact NPCI at the toll free number: 18001201740 and Mail Id: ipo.upi@npci.org.in; ICICI Bank Limited at Tel: + 91 22 6681 8911/23/24 and Email: kmr.saurabh@icicibank.com; and the Registrar to the Offer at Tel: +91 40 6716 2222 and Email: krsnaa.ipo@kfintech.com or einward.ris@kfintech.com.

Risks to Investors

- The 4 Book Running Lead Managers associated with the Offer have handled 32 public issues in the past three years, out of which 10 issues closed below the offer price on listing date.
- Average cost of acquisition of Equity Shares held by the Selling Shareholder PHI CAPITAL TRUST-PHI CAPITAL GROWTH FUND-I, Kitara PIIN 1104, SOMERSET INDUS HEALTHCARE FUND I LIMITED and LOTUS MANAGEMENT SOLUTIONS (ACTING THROUGH MAYUR SIRDESAI) is ₹ 157.26 per Equity Share, ₹ 67.35 per Equity Share, ₹ 67.35 per Equity Share and ₹ 67.35 per Equity Share, respectively and Offer Price at upper end of the Price Band is ₹ 954 per Equity Share.
- Weighted Average Return on Net Worth for Fiscals 2021, 2020 & 2019 is 9.54%.

CORRIGENDUM

Attention of investors is drawn to the footnote appended to the contingent liabilities table of the Company appearing on pages 21, 41 and 316 of the RHP and Note 1 appended to the contingent liabilities table of the Company appearing on page 281 of the RHP. At such pages, the value of the bank guarantee facility availed by the Company should be read as Rs. 334.00 million instead of Rs. 3,340 million.

For Krsnaa Diagnostics Limited

On behalf of the Board of Directors

Sd/-

Company Secretary and Compliance Officer

Place: Pune

Date: August 5, 2021

Krsnaa Diagnostics Limited is proposing, subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and other considerations, to make an initial public offering of its Equity Shares and has filed the RHP dated July 29, 2021 with RoC and thereafter with SEBI and the Stock Exchanges. The RHP shall be available on the website of SEBI at www.sebi.gov.in, websites of the Stock Exchanges i.e. BSE and NSE at www.bseindia.com and www.nseindia.com, respectively, and is available on the websites of the BRLMs i.e. JM Financial Limited, DAM Capital Advisors Limited (Formerly IDFC Securities Limited), Equirus Capital Private Limited and IIFL Securities Limited at www.jmf.com, www.damcapital.in, www.equirus.com, and www.iiflcap.com, respectively. Bidders should note that investment in equity shares involves a high degree of risk and for details refer to the RHP, including the section titled “Risk Factors” on page 24 of the RHP. Potential Bidders should not rely on the DRHP filed with SEBI for making any investment decision.

The Equity Shares offered in the Offer have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the “Securities Act”) or any other applicable law of the United States and, unless so registered, may not be offered or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and applicable state securities laws. Accordingly, the Equity Shares are only being offered and sold (i) within the United States only to persons reasonably believed to be “qualified institutional buyers” (as defined in Rule 144A under the Securities Act, “Rule 144A”) in transactions exempt from, or not subject to, registration requirements of the Securities Act, and (ii) outside the United States in offshore transactions in reliance on Regulation S under the Securities Act and pursuant to the applicable laws of the jurisdictions where those offers and sales are made. There will be no public offering of the Equity Shares in the United States.